Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,102 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Long-term outcomes with nivolumab plus ipilimumab versus sunitinib in first-line treatment of patients with advanced sarcomatoid renal cell carcinoma.
Rini BI, Signoretti S, Choueiri TK, McDermott DF, Motzer RJ, George S, Powles T, Donskov F, Tykodi SS, Pal SK, Gupta S, Lee CW, Jiang R, Tannir NM. Rini BI, et al. Among authors: pal sk. J Immunother Cancer. 2022 Dec;10(12):e005445. doi: 10.1136/jitc-2022-005445. J Immunother Cancer. 2022. PMID: 36549781 Free PMC article. Clinical Trial.
New therapies for castrate-resistant prostate cancer.
Williams SB, Lay AH, Lau CS, Josephson DY, Wilson TG, Choueiri TK, Pal SK. Williams SB, et al. Among authors: pal sk. Expert Opin Pharmacother. 2011 Sep;12(13):2069-74. doi: 10.1517/14656566.2011.590133. Epub 2011 Jun 11. Expert Opin Pharmacother. 2011. PMID: 21663529 Review.
Differentiating mTOR inhibitors in renal cell carcinoma.
Pal SK, Quinn DI. Pal SK, et al. Cancer Treat Rev. 2013 Nov;39(7):709-19. doi: 10.1016/j.ctrv.2012.12.015. Epub 2013 Feb 21. Cancer Treat Rev. 2013. PMID: 23433636 Free PMC article. Review.
1,102 results